Abstract: A spectrometry system for spectroscopically analyzing a sample is provided. The system includes an excitation source for interacting with the sample; a detector for detecting at least a portion of light absorbed or emitted by the sample, the excitation source and detector being optically coupled via an optical pathway; and an aperture positioned in the optical pathway for limiting transmission of light from the excitation source to the detector; wherein the aperture is configured to have a spatially varying distribution of one or more geometric features that provide regions of variable transmission around an edge of the aperture. Also provided is a mask for use with a spectrometry system, the mask configured to be positioned in an optical pathway between an excitation source and a detector, wherein the mask has a spatially varying distribution of one or more geometric features that provide regions of variable transmission around an edge of the aperture.

Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.

Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.

Abstract: A method of synthesising a compound of formula (I) from a compound of formula (II) wherein R2 is phenyl, substituted at either the meta- or para-position by the group (III) where Q is an amino acid residue (—C(?O)—X1—NH—), a di-amino acid residue (—C(?O)—X1—X2—NH—) or a tri-amino acid residue (—C(?O)—X1—X2—X3—NH—); ProtN3 is an amino protecting group; R2pre is phenyl, substituted at the same position as R2 by —NH2; comprising reacting a compound of formula (II) with a compound of formula (IV) in the presence of HATU in dichloromethane or chloroform or a mixture thereof.

Abstract: A compound of formula (I) and salts and solvates thereof, wherein RL is a linker for connection to a cell binding agent, which is formula (IIa) wherein Q is a tripeptide residue of formula (A), where x is 1 or 2, —C(?O)-Qx-NH— is a dipeptide residue; X is: formula (B), where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5; and GL is a linker for connecting to a Ligand Unit.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A compound of formula (I) wherein RL is a linker for connection to a cell binding agent.

Abstract: A method, including: receiving observation data from one or more data-capturing devices, the observation data representing a presence of an individual; processing the observation data to generate identity data representing the identity of the individual, and to detect at least one physiological characteristic or behavioural characteristic of the individual; retrieving behavioural profile data of the individual based on the identity data; and comparing the detected characteristic to at least one expected characteristic represented by the behavioural profile data of the individual to identify an abnormality of the individual.

Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.

Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: A conjugate of formula (I), wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R10 is OH, and R11 is formula (A): p is an integer of from 1 to 20.

Abstract: A method and system for providing proof of personal information includes a first device sending a request to a server for proving user information and data identifying a requester. The server generates (i) requester authentication data and associated data identifying a transaction, and (ii) a proof of user information using the user information and the requester authentication data. The server then sends the proof of user information and the associated data identifying the transaction to the first device. A second device sends to the server a request for getting authentication data associated with data identifying a transaction and the associated data identifying the transaction. In response to the request, the server sends authentication data associated with the data identifying the transaction to the second device. The second device or a verifier may then authenticate the user information only if the received authentication data matches the requester authentication data.

Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.

Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

Abstract: A compound with the formula I: (I) and salts and solvates thereof, wherein: R? is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.

Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.